Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 4—April 2021
CME ACTIVITY - Research

Infections with Tickborne Pathogens after Tick Bite, Austria, 2015–2018

Author affiliations: Medical University of Vienna, Vienna, Austria (M. Markowicz, A.-M. Schötta, M. Kundi, C. Schray, H. Stockinger, G. Stanek); Private Medical Office, Thiersee, Austria (D. Höss)

Cite This Article

Introduction

CME Logo

Medscape CME ACTIVITY

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at https://www.medscape.org/journal/eid; and (4) view/print certificate.

Release date: March 18, 2021; Expiration date: March 18, 2022
Learning Objectives

Upon completion of this activity, participants will be able to:

  • Assess characteristics of tick bites in the current study

  • Analyze results of molecular screening of ticks in the current study

  • Distinguish the rate of positive testing for Borrelia among patients in the current study

  • Evaluate risk factors for a positive Borrelia infection in the current study.

CME Editor

Thomas J. Gryczan, MS, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Thomas J. Gryczan, MS, has disclosed no relevant financial relationships.

CME Author

Charles P. Vega, MD, Health Sciences Clinical Professor of Family Medicine, University of California, Irvine School of Medicine, Irvine, California. Disclosure: Charles P. Vega, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for GlaxoSmithKline.

Authors

Disclosures: Mateusz Markowicz, MD; Anna-Margarita Schötta, BSc; Dieter Höss, MD; Christina Schray, MD; and Hannes Stockinger, PhD, have disclosed no relevant financial relationships. Michael Kundi, PhD, has disclosed the following relevant financial relationships: served as an advisor or consultant for AVIR Green Hills Biotechnology AG; Valneva SE; Vivaldi Biosciences Inc.; received grants for clinical research from Pfizer Inc. Gerold Stanek, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Valneva SE.

Top

Abstract

The aim of this prospective study was to assess the risk for tickborne infections after a tick bite. A total of 489 persons bitten by 1,295 ticks were assessed for occurrence of infections with Borrelia burgdorferi sensu lato, Anaplasma phagocytophilum, Rickettsia spp., Babesia spp., Candidatus Neoehrlichia mikurensis, and relapsing fever borreliae. B. burgdorferi s.l. infection was found in 25 (5.1%) participants, of whom 15 had erythema migrans. Eleven (2.3%) participants were positive by PCR for Candidatus N. mikurensis. One asymptomatic participant infected with B. miyamotoi was identified. Full engorgement of the tick (odds ratio 9.52) and confirmation of B. burgdorferi s.l. in the tick by PCR (odds ratio 4.39) increased the risk for infection. Rickettsia helvetica was highly abundant in ticks but not pathogenic to humans. Knowledge about the outcome of tick bites is crucial because infections with emerging pathogens might be underestimated because of limited laboratory facilities.

Ticks are vectors for a variety of tickborne pathogens that cause human disease (1). The diversity of tickborne pathogens has increased extensively in recent years, supported by progress in the molecular identification of microorganisms (2). Clinical studies on the health-related impact of many emerging tickborne pathogens are scarce and information on the epidemiology is limited.

We undertook a comprehensive observational study in Austria to assess the incidence of recognized tickborne infections by applying clinical, serologic, and microbiological endpoints. We conducted a detailed risk analysis of contracting Lyme borreliosis. Our objective was to investigate whether variables such as confirmation of Borrelia burgdorferi sensu lato in ticks, duration of tick attachment, engorgement of ticks, and number of simultaneous tick bites have an impact on the risk for infection. Furthermore, we wanted to know whether the localization of a given tick bite and any previous contact with B. burgdorferi s.l. can affect this risk.

Methods

Participants were enrolled prospectively during 2015–2018 at 2 centers in Austria (Vienna and Thiersee). The invitation to participate was announced in the local media. The analysis focused on infections with tickborne pathogens including B. burgdorferi s.l., Anaplasma phagocytophilum, Rickettsia spp., Babesia spp., Candidatus Neoehrlichia mikurensis, and relapsing fever borreliae. The study was approved by the ethics committee of the Medical University of Vienna (1064/2015) and of the Medical University of Innsbruck (AN2016-0043-359/4.16). Participants provided written informed consent.

Inclusion/Exclusion Criteria

Inclusion criteria were a minimum age of 18 years and the availability of the particular tick for testing. Persons bitten >7 days before assessment were excluded.

Questionnaire

A standardized questionnaire was used to collect information concerning tick bite location, history of erythema migrans, antimicrobial drug treatment within 4 weeks before the tick bite, estimated duration of tick attachment, number of ticks removed, and possible geographic region of tick attack. The feeding duration of the tick was reported in days by the difference of the estimated date of the tick bite and the date of tick removal.

Outcome Definition

Serologic testing and PCR for blood were conducted during the first week after the removal of the tick, with a follow-up scheduled 6 weeks thereafter. We defined infection as >1 of the following: occurrence of erythema migrans diagnosed by a medical professional (M.M. or D.H.), increase in Borrelia-specific antibodies in follow-up samples, and presence of the microorganism determined by PCR in the initial or follow-up blood samples.

Laboratory Analyses

Laboratory analyses were conducted at the Institute of Hygiene and Applied Immunology in Vienna. An experienced technician (A.-M.S.) identified ticks morphologically. If identification was inconclusive, we used molecular methods. Ten percent of the randomly selected Ixodes ricinus ticks underwent molecular identification to confirm the identification procedure. We documented the developmental stage of the ticks and recorded engorgement levels as not engorged, partially engorged, or fully engorged.

We extracted DNA from the ticks as described (2). Molecular identification of ticks was conducted by using the mitochondrial 16S rRNA gene (3), 12S rDNA gene (4), internal transcribed spacer 2 region (5), or cytochrome c oxidase subunit 1 gene (6). PCR products were purified and sent to Microsynth (https://www.microsynth.at) for bidirectional sequencing.

Molecular detection of B. burgdorferi s.l.; Rickettsia spp.; Anaplasma/Ehrlichia spp., including Candidatus N. mikurensis, Babesia spp., and Coxiella burnetti; was performed by using reverse line blot (RLB) hybridization (2). Sequencing was conducted if RLB failed to yield a species-specific signal. When Rickettsia spp. could not be identified by sequencing the 23S–5S intergenic spacer region used for RLB (7), we conducted additional PCRs specific for the gltA gene (8,9). We used real-time PCRs to detect B. miyamotoi (10) and, in addition to RLB hybridization, for Candidatus N. mikurensis (11).

Molecular Analysis of Blood

We screened extracted DNA from blood containing EDTA for tickborne pathogens by using real-time PCR. The pathogens screened were B. burgdorferi s.l. (12), Rickettsia spp. (12), relapsing fever borreliae (12), A. phagocytophilum (13), B. miyamotoi (10), and Candidatus N. mikurensis (11).

Serologic Testing

We assessed infections with B. burgdorferi s.l. by comparing ELISA values for IgM and IgG at the first and the follow-up tests. The increase in antibody levels was observed when the first sample yielded a negative result by using the cutoff value provided by the manufacturer and the result was positive in the follow-up sample. For specimens with a value above the cutoff value in the initial sample, we defined the infection as a 25% increase. Positive and borderline ELISA results were confirmed by using immunoblot (Anti-Borrelia-EUROLINE-RN-AT; Euroimmun, https://www.euroimmun.com).

During this study, a change of test systems was necessary because of withdrawal of systems from the market. A Borrelia ELISA (Medac, https://international.medac.de) was used until the end of May 2018, followed by Anti-Borrelia-plusVlsE-ELISA (Euroimmun) after June 2018. In the instance that the first and the follow-up serum samples were analyzed by different ELISAs, we used a paired sample for retesting with the new ELISA.

We performed serologic testing for other tickborne pathogens by applying the following commercial tests: A. phagocytophilum and Rickettsia IgG immunofluorescence assays (Focus Diagnostics, https://www.focusdx.com) and the Weil-Felix agglutination assay (DiaMondiaL, https://www.diamondial.com) as an additional serologic test able to detect infections with Rickettsia spp. Infections were defined as a 4-fold change in the titer.

Determination of Sample Size

Human infection rates for B. burgdorferi s.l. after tick bites have been reported to be 2%–5% (14,15). Because high endemicity can be assumed for the covered regions, we determined the sample size on the basis of an upper limit of 5%. To have a power of 80% to detect an effect associated with an odds ratio (OR) >2, and considering covariates with a combined R2 of 25%, a total of 411 participants were considered necessary to provide statistical significance at the (2-sided) 5% level.

Statistical Analysis

Because many participants had >1 tick on >1 occasion, we considered only ticks brought at the time of infection for infected persons. For noninfected persons who had >1 visit, 1 visit was chosen randomly, and the tick removed on that occasion was used for analysis. Similarly, if several ticks were available for the visit, 1 tick was randomly selected unless 1 of them was infected.

Preliminary comparisons of Borrelia-infected and noninfected participants were performed by using the Mann-Whitney test for metric data. We used the Fisher exact probability test for dichotomous data and the Fisher-Freeman-Halton test for categorical data. These data are reported as mean ± SD and median (interquartile range) with absolute and percent frequencies. Multiple logistic regression analysis was conducted to assess the risk for infection associated with attributes of the ticks, taking the age and sex of the participants into account. Seven persons did not complete follow-up testing and were excluded from the analyses. No imputation for missing data was applied. All analyses were performed by using Stata 13.1 (StataCorp LLC, https://www.stata.com).

Results

Study Population

A total of 489 participants were included in the study, of whom 7 were unavailable for follow-up. The number of ticks removed by the participants was 1,295. The final total of 482 study participants (255 women and 227 men) had a mean age of 49 years (range 19–83 years) and had been bitten by 1,279 ticks. A total of 433 (89.8%) participants were enrolled in Vienna and 49 (10.2%) were enrolled in Tyrol. At baseline, 120 (24.9%) participants were seropositive for Borrelia antibodies, 39 (8.1%) for A. phagocytophilum antibodies, and 13 (2.7%) for Rickettsia spp. antibodies. The mean time interval between the baseline and the follow-up test was 47 days (range 21–147 days).

Ticks Obtained from Participants

A total of 96% of the tick bites occurred in Austria. Most ticks were removed during the months of June (338, 26.4%) and May (303, 23.7%), followed by July (227, 17.7%) and August (115, 9.0%).

Of the 1,279 ticks, 1,277 (99.8%) were I. ricinus. The 2 remaining ticks were H. concinna and a nymphal Haemaphysalis sp. tick imported from Cambodia. The most common developmental stage was the nymphal stage (922 ticks, 72.1%) followed by larvae (241 ticks, 18.8%), and adults (112 ticks [103 females and 9 males], 8.8%). For 4 ticks (0.3%), it was not possible to identify the developmental stage, but I. ricinus was confirmed by PCR.

We compiled an overview of tick collection (Figure 1). Of the 482 participants, 139 persons collected >1 tick. The highest number of ticks per person was 163. Nearly half of the ticks were removed on the first day (629, 49.2%) (Figure 2).

Molecular Screening of Ticks

B. burgdorferi s.l.was detected in 15.2% (194/1,279) of all ticks. The most common genospecies was B. afzelii in 66.5% (129/194), followed by B. garinii/B. bavariensis in 16.5% (32 ticks), B. burgdorferi sensu stricto in 7.7% (15 ticks), and other Borrelia spp. in 11.3% (22 ticks). Co-infections with >1 genospecies were detected in 4 ticks.

Rickettsia spp. was the second most frequent organism with 9.4% (120/1,279), and R. helvetica represented 86.7% (104/120) of all Rickettsia-positive ticks, followed by R. monacensis in 8 ticks (6.7%). Eight Rickettsia-positive samples yielded only genus-specific signals on the RLBs. Presence of Candidatus R. mendelii was confirmed by sequencing 4 of these ticks. Two were new species according to phylogenetic guidelines (16), of which 1 belonged to the spotted fever group Rickettsiae (17). For the remaining 2 Rickettsia-positive ticks, the species could not be identified. We provide an overview of the tickborne pathogens detected in the different life stages of the ticks (Table 1).

Of the 1,279 ticks included in the study, 380 (29.7%) harbored >1 tickborne pathogen. Dual infections with organisms of different genera occurred in 48 ticks (3.8%). Seven ticks (0.6%) harbored 3 different genera.

Human Infection

Borrelia infection was found in 25 (5.1%) participants. Fifteen patients had erythema migrans, of whom 9 also showed an increase in Borrelia-specific antibodies in the follow-up sample. All instances of erythema migrans except 1 were localized at the site of the tick bite. Moreover, in 10 persons, evidence of Borrelia infection was found by serologic testing, and these persons did not have erythema migrans or any other symptoms. Demonstration of B. burgdoferi s.l. by PCR in the blood was successful in only 1 participant who had erythema migrans in an early stage. Infection with B. burgdorferi s.l. occurred twice in 2 participants. One woman had an erythema migrans twice within 4 months. Another woman had an asymptomatic infection, followed by erythema migrans 3 weeks later. She had been bitten by 11 ticks and showed seroconversion. Thereafter, she had another tick bite, which caused also erythema migrans around the bite. Antimicrobial drugs were given to patients who had erythema migrans but not to those who had asymptomatic infections.

With regard to other infections, 11 (2.3%) participants were positive for Candidatus N. mikurensis. These participants reported no symptoms. For 3 participants, the presence of Candidatus N. mikurensis was identified at the first visit, as well as at the follow-up tests. The time intervals between the examinations for these 3 participants were 41, 44, and 86 days. One study participant was positive for B. miyamotoi by PCR but reported no signs or symptoms. No infections with A. phagocytophilum or Rickettsia spp. were documented. No infections with C. burnettii or Babesia spp. were found by PCR; however, serologic testing was not used for these infections.

Risk for Infection with B. burgdorferi s.l.

We compared the demographic and other variables between the participants with Borrelia infection and noninfected participants (Table 2). In a multivariate model, the tick engorgement levels (OR 9.52) and confirmation of B. burgdorferi s.l. in ticks (OR 4.39) showed a major increase in the risk for infection (Table 3).

We also compared the differences in the distribution of ticks co-infected with multiple pathogens that had bitten participants with and without Borrelia infection. Of 37 ticks detached by 25 Borrelia-infected participants, 4 (10.8%) harbored >1 pathogen, whereas among 1,242 ticks from the noninfected group, 56 (4.5%) carried multiple pathogens (p = 0.07).

Discussion

We investigated 482 persons bitten by ticks for the occurrence of bacterial tickborne infections and Babesia spp. We demonstrated a high incidence of infections with the emerging pathogen, Candidatus N. mikurensis. Furthermore, our data clearly show that R. helvetica, though highly abundant in ticks in Austria, does not pose a risk for human health. We also conducted a detailed risk analysis for contracting Lyme borreliosis by analyzing numerous demographic and clinical parameters. This knowledge is needed for further research on the efficacy of specific interventions for preventing Lyme borreliosis, such as local or systemic antimicrobial drug prophylaxis after tick bite (18).

The risk for contracting Borrelia infection was 5.1%, which is consistent with published data for the Netherlands and Sweden (14,15), despite a different frequency of B. burgdorferi s.l. in ticks (15.2%) compared with previous reports (26% and 29.3%). This finding might be explained by the fact that more larvae were removed during the current study. I. ricinus larvae do not harbor B. burgdorferi s.l. because of lack of transovarial transmission of this pathogen. An investigation of ticks collected from vegetation throughout Austria showed that 25% of ticks were positive for Borrelia spp. (2), but no larvae were analyzed. Because male adult I. ricinus ticks rarely feed on humans, only 9 of 112 adult ticks detached by study participants were male.

The presence of Borrelia in ticks and the level of tick engorgement were the major predictors of infection. However, we did not find a correlation between infection and the time of attachment reported by the participants. Clinical trials on the relationship between infection risk and duration of tick feeding are scarce, and results are contradictory (14,15). Inconsistency might be attributed to the fact that self-assessment of the duration of tick attachment might be imprecise. We assume that if more granular time intervals (e.g., in hours instead of days) had been applied in our study, the results might have been different, particularly for the large group of persons who had removed their ticks within the first 24 hours (≈50% of the ticks in this study). Transmission of B. burgdorferi s.l. can occur <24 hours from tick attachment (14,19). Our study demonstrates that morphologic evaluation of tick engorgement is more reliable as a predictor for risk of infection. The risk was 10 times higher for fully engorged ticks than for nonengorged ticks. Limited correlation between self-reported duration of tick attachment and level of engorgement has been reported (20).

Our data suggest that a history of erythema migrans and presence of antibodies do not avert further Borrelia infections. The frequency of participants who had been seropositive at baseline and of those who had previous erythema migrans was higher in the infected group (Table 2). Although not statistically significant, these results suggest greater exposure to ticks.

Among other tickborne pathogens, Candidatus N. mikurensis was the most frequent agent identified in blood containing EDTA, and 2% of the participants had an asymptomatic infection with this emerging pathogen. Infection with Candidatus N. mikurensis can have a severe clinical picture. Life-threatening complications can occur not only for immunocompromised patients but also for immunocompetent patients (21,22). The pathogen was detected in blood samples of patients who had erythema migrans–like rashes in Norway; a total of 70 symptomatic patients were tested, and the pathogen was found in 10% of the patients (23). Asymptomatic infections are rare and they have been reported in healthy foresters from Poland (24), but no prospective data on the risk for acquiring the infection after tick bites are available. For 3 persons, we detected the pathogen in 2 consecutive samples. In 1 of these persons, the first positive sampling occurred during October, and the follow-up was performed 86 days later in January. Because no tick bites were documented in this study during the months of December–February, this finding suggests a long persistence of the pathogen in the blood in the absence of symptoms. However, there are no comparable reports on the persistence of Candidatus N. mikurensis in a human host.

B. miyamotoi is transmitted uniquely by Ixodes ticks and is an emerging pathogen causing febrile illness and meningitis in immunocompromised patients (25,26). With a prevalence of 2% in ticks, we expected a low incidence of infections in humans. We detected this spirochete in a healthy 79-year-old man. The incidence for infections with A. phagocytophilum was low, which corresponds to observations from Scandinavian countries (27). We did not document any case despite a relatively high level of background seroprevalence at study inclusion (8%). Severe cases of human granulocytic anaplasmosis sporadically occur in Austria (28), and a larger sample size might be necessary to detect such cases.

Rickettsia spp. was found in 9.4% of the ticks in our study. However, we did not identify any infections by using serologic or molecular methods. No study participant showed development of clinical signs of rickettsial infection, such as skin eschars or lymphadenopathy. The dominating species in ticks from Austria was R. helvetica, and only a few infections with this organism have been reported worldwide, suggesting its low pathogenicity (16,29).

We identified Candidatus R. mendelii in 4 ticks. This novel organism was initially identified in the Czech Republic during 2016 (30). Extensive data on its geographic distribution are missing. We also detected a new Rickettsia sp. of the spotted fever group in a tick from Tyrol, Austria (17).

We did not exclude patients who had received previous antimicrobial drug treatment. A total of 23 of these patients received antimicrobial drugs that were active against tickborne pathogens starting 4 weeks before enrollment. Six participants were receiving antimicrobial drugs at study inclusion, and the time point for antimicrobial drug treatment was not known exactly for 7 participants. Two participants were receiving immunosuppressive treatment. For persons with multiple tick bites in the noninfected group, we randomly selected 1 tick for risk analysis because it would otherwise have been difficult to calculate a regression model. Finally, for some pathogens, we used PCR only to identify infections without additional serologic testing, including that for Babesia spp. and B. miyamotoi. Because of a low prevalence of these pathogens in ticks, it is unlikely that we would have found a substantial amount of infections by using serologic methods.

Top

Acknowledgment

We thank Katharina Grabmeier-Pfistershammer and Julia Parzinger for their help in enrolling the study participants.

Top

References

  1. Stanek  G, Wormser  GP, Gray  J, Strle  F. Lyme borreliosis. Lancet. 2012;379:46173. DOIPubMedGoogle Scholar
  2. Schötta  A-M, Wijnveld  M, Stockinger  H, Stanek  G. Approaches for reverse line blot-based detection of microbial pathogens in Ixodes ricinus ticks collected in Austria and impact of the chosen method. Appl Environ Microbiol. 2017;83:e0048917. DOIPubMedGoogle Scholar
  3. Black  WC IV, Piesman  J. Phylogeny of hard- and soft-tick taxa (Acari: Ixodida) based on mitochondrial 16S rDNA sequences. Proc Natl Acad Sci U S A. 1994;91:100348. DOIPubMedGoogle Scholar
  4. Beati  L, Keirans  JE. Analysis of the systematic relationships among ticks of the genera Rhipicephalus and Boophilus (Acari: Ixodidae) based on mitochondrial 12S ribosomal DNA gene sequences and morphological characters. J Parasitol. 2001;87:3248. DOIPubMedGoogle Scholar
  5. Lv  J, Wu  S, Zhang  Y, Chen  Y, Feng  C, Yuan  X, et al. Assessment of four DNA fragments (COI, 16S rDNA, ITS2, 12S rDNA) for species identification of the Ixodida (Acari: Ixodida). Parasit Vectors. 2014;7:93. DOIPubMedGoogle Scholar
  6. Chitimia  L, Lin  R-Q, Cosoroaba  I, Wu  XY, Song  HQ, Yuan  ZG, et al. Genetic characterization of ticks from southwestern Romania by sequences of mitochondrial cox1 and nad5 genes. Exp Appl Acarol. 2010;52:30511. DOIPubMedGoogle Scholar
  7. Jado  I, Escudero  R, Gil  H, Jiménez-Alonso  MI, Sousa  R, García-Pérez  AL, et al. Molecular method for identification of Rickettsia species in clinical and environmental samples. J Clin Microbiol. 2006;44:45726. DOIPubMedGoogle Scholar
  8. Labruna  MB, McBride  JW, Bouyer  DH, Camargo  LM, Camargo  EP, Walker  DH. Molecular evidence for a spotted fever group Rickettsia species in the tick Amblyomma longirostre in Brazil. J Med Entomol. 2004;41:5337. DOIPubMedGoogle Scholar
  9. Labruna  MB, Whitworth  T, Horta  MC, Bouyer  DH, McBride  JW, Pinter  A, et al. Rickettsia species infecting Amblyomma cooperi ticks from an area in the state of São Paulo, Brazil, where Brazilian spotted fever is endemic. J Clin Microbiol. 2004;42:908. DOIPubMedGoogle Scholar
  10. Reiter  M, Schötta  A-M, Müller  A, Stockinger  H, Stanek  G. A newly established real-time PCR for detection of Borrelia miyamotoi in Ixodes ricinus ticks. Ticks Tick Borne Dis. 2015;6:3038. DOIPubMedGoogle Scholar
  11. Silaghi  C, Woll  D, Mahling  M, Pfister  K, Pfeffer  M. Candidatus Neoehrlichia mikurensis in rodents in an area with sympatric existence of the hard ticks Ixodes ricinus and Dermacentor reticulatus, Germany. Parasit Vectors. 2012;5:285. DOIPubMedGoogle Scholar
  12. Leschnik  MW, Khanakah  G, Duscher  G, Wille-Piazzai  W, Hörweg  C, Joachim  A, et al. Species, developmental stage and infection with microbial pathogens of engorged ticks removed from dogs and questing ticks. Med Vet Entomol. 2012;26:4406. DOIPubMedGoogle Scholar
  13. Pusterla  N, Huder  JB, Leutenegger  CM, Braun  U, Madigan  JE, Lutz  H. Quantitative real-time PCR for detection of members of the Ehrlichia phagocytophila genogroup in host animals and Ixodes ricinus ticks. J Clin Microbiol. 1999;37:132931. DOIPubMedGoogle Scholar
  14. Hofhuis  A, Herremans  T, Notermans  DW, Sprong  H, Fonville  M, van der Giessen  JW, et al. A prospective study among patients presenting at the general practitioner with a tick bite or erythema migrans in The Netherlands. PLoS One. 2013;8:e64361. DOIPubMedGoogle Scholar
  15. Wilhelmsson  P, Fryland  L, Lindblom  P, Sjöwall  J, Ahlm  C, Berglund  J, et al. A prospective study on the incidence of Borrelia burgdorferi sensu lato infection after a tick bite in Sweden and on the Åland Islands, Finland (2008-2009). Ticks Tick Borne Dis. 2016;7:719. DOIPubMedGoogle Scholar
  16. Fournier  PE, Grunnenberger  F, Jaulhac  B, Gastinger  G, Raoult  D. Evidence of Rickettsia helvetica infection in humans, eastern France. Emerg Infect Dis. 2000;6:38992. DOIPubMedGoogle Scholar
  17. Schötta  AM, Wijnveld  M, Höss  D, Stanek  G, Stockinger  H, Markowicz  M. Identification and characterization of “Candidatus Rickettsia thierseensis”, a novel spotted fever group Rickettsia species detected in Austria. Microorganisms. 2020;8:E1670. DOIPubMedGoogle Scholar
  18. Schwameis  M, Kündig  T, Huber  G, von Bidder  L, Meinel  L, Weisser  R, et al. Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial. Lancet Infect Dis. 2017;17:3229. DOIPubMedGoogle Scholar
  19. Nahimana  I, Gern  L, Blanc  DS, Praz  G, Francioli  P, Péter  O. Risk of Borrelia burgdorferi infection in western Switzerland following a tick bite. Eur J Clin Microbiol Infect Dis. 2004;23:6038. DOIPubMedGoogle Scholar
  20. Sood  SK, Salzman  MB, Johnson  BJ, Happ  CM, Feig  K, Carmody  L, et al. Duration of tick attachment as a predictor of the risk of Lyme disease in an area in which Lyme disease is endemic. J Infect Dis. 1997;175:9969. DOIPubMedGoogle Scholar
  21. Wennerås  C. Infections with the tick-borne bacterium Candidatus Neoehrlichia mikurensis. Clin Microbiol Infect. 2015;21:62130. DOIPubMedGoogle Scholar
  22. von Loewenich  FD, Geissdörfer  W, Disqué  C, Matten  J, Schett  G, Sakka  SG, et al. Detection of “Candidatus Neoehrlichia mikurensis” in two patients with severe febrile illnesses: evidence for a European sequence variant. J Clin Microbiol. 2010;48:26305. DOIPubMedGoogle Scholar
  23. Quarsten  H, Grankvist  A, Høyvoll  L, Myre  IB, Skarpaas  T, Kjelland  V, et al. Candidatus Neoehrlichia mikurensis and Borrelia burgdorferi sensu lato detected in the blood of Norwegian patients with erythema migrans. Ticks Tick Borne Dis. 2017;8:71520. DOIPubMedGoogle Scholar
  24. Welc-Falęciak  R, Siński  E, Kowalec  M, Zajkowska  J, Pancewicz  SA. Asymptomatic “Candidatus Neoehrlichia mikurensis” infections in immunocompetent humans. J Clin Microbiol. 2014;52:30724. DOIPubMedGoogle Scholar
  25. Platonov  AE, Karan  LS, Kolyasnikova  NM, Makhneva  NA, Toporkova  MG, Maleev  VV, et al. Humans infected with relapsing fever spirochete Borrelia miyamotoi, Russia. Emerg Infect Dis. 2011;17:181623. DOIPubMedGoogle Scholar
  26. Henningsson  AJ, Asgeirsson  H, Hammas  B, Karlsson  E, Parke  Å, Hoornstra  D, et al. Two cases of Borrelia miyamotoi meningitis, Sweden, 2018. Emerg Infect Dis. 2019;25:19658. DOIPubMedGoogle Scholar
  27. Henningsson  AJ, Wilhelmsson  P, Gyllemark  P, Kozak  M, Matussek  A, Nyman  D, et al. Low risk of seroconversion or clinical disease in humans after a bite by an Anaplasma phagocytophilum-infected tick. Ticks Tick Borne Dis. 2015;6:78792. DOIPubMedGoogle Scholar
  28. Hoepler  W, Markowicz  M, Schoetta  AM, Zoufaly  A, Stanek  G, Wenisch  C. Molecular diagnosis of autochthonous human anaplasmosis in Austria - an infectious diseases case report. BMC Infect Dis. 2020;20:288. DOIPubMedGoogle Scholar
  29. Parola  P, Paddock  CD, Raoult  D. Tick-borne rickettsioses around the world: emerging diseases challenging old concepts. Clin Microbiol Rev. 2005;18:71956. DOIPubMedGoogle Scholar
  30. Hajduskova  E, Literak  I, Papousek  I, Costa  FB, Novakova  M, Labruna  MB, et al. Candidatus Rickettsia mendelii’, a novel basal group rickettsia detected in Ixodes ricinus ticks in the Czech Republic. Ticks Tick Borne Dis. 2016;7:4826. DOIPubMedGoogle Scholar

Top

Figures
Tables

Top

Follow Up

Earning CME Credit

To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions (with a minimum 75% passing score) and earn continuing medical education (CME) credit, please go to https://www.medscape.org/journal/eid. Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers.

You must be a registered user on http://www.medscape.org. If you are not registered on http://www.medscape.org, please click on the “Register” link on the right hand side of the website.

Only one answer is correct for each question. Once you successfully answer all post-test questions, you will be able to view and/or print your certificate. For questions regarding this activity, contact the accredited provider, CME@medscape.net. For technical assistance, contact CME@medscape.net. American Medical Association’s Physician’s Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please go to https://www.ama-assn.org. The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit may be acceptable as evidence of participation in CME activities. If you are not licensed in the US, please complete the questions online, print the AMA PRA CME credit certificate, and present it to your national medical association for review.

Article Title: 
Infections with Tickborne Pathogens after Tick Bite, Austria, 2015–2018
CME Questions
  • Which of the following statements regarding ticks assessed in the current study is most accurate?

    • > 99% of ticks collected were Ixodes ricinus

    • The most common developmental stage was adult

    • Most ticks were male

    • Most patients collected > 1 tick

  • Which of the following statements regarding molecular screening of ticks in the current study is most accurate?

    • ≈60% of ticks examined harbored a tickborne pathogen (TBP)

    • Borrelia burgdorferi was detected in 15% of ticks

    • B. burgdorferi sensu stricto was the most common genospecies isolated in the current series

    • Rickettsia spp. was the most common TBP isolated

  • What approximate percentage of patients in the current series with tick bites were positive for Borrelia infection?

    • 0.1%

    • 1%

    • 5%

    • 17%

  • Which of the following variables was most associated with a significantly higher risk for Borrelia infection in the current study?

    • Female sex and older age

    • Older age and tick bite on the head or neck

    • A higher number of ticks and confirmation of Borrelia infection in ticks

    • Tick engorgement and confirmation of Borrelia infection in ticks

Top

Cite This Article

DOI: 10.3201/eid2704.203366

Original Publication Date: March 18, 2021

Related Links

Table of Contents – Volume 27, Number 4—April 2021

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Mateusz Markowicz, Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Kinderspitalgasse 15, Vienna A-1090, Austria

Send To

10000 character(s) remaining.

Top

Page created: January 11, 2021
Page updated: March 18, 2021
Page reviewed: March 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external